.Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX08_Tafamidis.Tafamidis .Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX08_Tafamidis.Tafamidis| name: | Tafamidis | |
| ATC code: | N07XX08 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 16.8 | L |
| clearance: | 0.228 | L/h |
| other parameters in model implementation | ||
Tafamidis is a selective transthyretin (TTR) stabilizer used for the treatment of transthyretin amyloidosis (ATTR), including hereditary and wild-type forms. It prevents dissociation of the TTR tetramer, thereby inhibiting amyloid fibril formation in patients with transthyretin-mediated amyloidosis, particularly associated with polyneuropathy or cardiomyopathy. It is an approved and currently used medication.
Pharmacokinetic parameters for healthy adult volunteers; oral single-dose of tafamidis meglumine 20 mg.
Lockwood, PA, et al., & Riley, S (2020). The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers. Clinical pharmacology in drug development 9(7) 849–854. DOI:10.1002/cpdd.789 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32196976